Anita Varma, MD
Psychiatry · Memphis, TNNPI 1760498182
Payments from drug & device makers
Across 801 payments — averaging $1565.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$457K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$380K
- Acadia Pharmaceuticals Inc$245K
- Avanir Pharmaceuticals, Inc.$58K
- Sage Therapeutics, LLC$39K
- Supernus Pharmaceuticals, Inc.$30K
- plus $45K from 21 others
Across 7 payments — averaging $4620.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arbor Pharmaceuticals, Inc.$32K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 258 | $457,240 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $379,740 |
| Acadia Pharmaceuticals Inc | 30 | $244,755 |
| Avanir Pharmaceuticals, Inc. | 20 | $57,974 |
| Sage Therapeutics, LLC | 7 | $38,790 |
| Supernus Pharmaceuticals, Inc. | 21 | $30,467 |
| Teva Pharmaceuticals USA, Inc. | 36 | $27,713 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $10,653 |
| Johnson & Johnson | 60 | $1,118 |
| Otsuka America Pharmaceutical, Inc. | 76 | $987 |
| Alkermes, Inc. | 37 | $746 |
| Lundbeck LLC | 40 | $710 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $701 |
| Neurocrine Biosciences, Inc. | 30 | $685 |
| Sunovion Pharmaceuticals Inc. | 33 | $649 |
| Vanda Pharmaceuticals Inc. | 28 | $501 |
| Tris Pharma Inc | 15 | $245 |
| Bausch Health US, LLC | 10 | $190 |
| Ironshore Pharmaceuticals Inc. | 8 | $118 |
| E.r. Squibb & Sons, L.L.C. | 3 | $68 |
| Eisai Inc. | 3 | $59 |
| Merck | 3 | $50 |
| Corium, LLC | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Indivior Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$1,254,321 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Memphis
- Daniel BoydMemphis$69K
- Melissa ShelbyMemphis$14K
- Kenny TerryMemphis$14K
- Robert HoehnMemphis$12K
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- Paul NewhouseNashville$1.4M
- John FenleyJohnson City$1.4M
- Patricia AndrewsNashville$748K
- David SnowMaryville$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.